Hassane M. Zarour, MD, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma.
Hassane M. Zarour, MD, professor of medicine and immunology at the University of Pittsburgh, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma.
According to Zarour, clinicians should think twice about whether the patient needs antibiotics, because they could be deleterious to a specific therapy.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More